Original Article

Incidence of Constipation Associated with Long-acting Opioid Therapy: A Comparative Study

Authors: Peter S. Staats, MD, Jeffrey Markowitz, DRPH, Jeffrey Schein, DRPH, MPH

Abstract

Background: Opioid therapy plays a key role in the management of chronic pain. Constipation is one of the more frequently occurring adverse effects associated with opioid therapy.


Methods: A retrospective cohort design study was conducted to determine the incidence of constipation in chronic pain patients who received three different long-acting opioids (transdermal fentanyl, oxycodone HCl controlled-release [CR], or morphine CR) for malignant or nonmalignant chronic pain. The data source was claims data (January 1996 through March 2001) from a 20% random sample of the California Medicaid (Medi-Cal) database. Claims data were from adult patients with chronic pain (malignant or nonmalignant) who had no prior diagnosis of constipation and no prior usage of long-acting opioids for at least 3 months before the observation period. Patients were followed for at least 3 months after the initiation of opioid therapy. ICD-9 code for diagnosis of constipation was the main outcome variable. Crude rates of constipation, annual incidence density, relative risk, and adjusted odds ratios were compared.


Results: A total of 1,836 patients (601 receiving transdermal fentanyl, 721 receiving oxycodone CR, and 514 receiving morphine CR) were included in the analysis. Crude (unadjusted) rates of constipation were 3.7% for transdermal fentanyl, 6.1% for oxycodone CR, and 5.1% for morphine CR (P > 0.05). Transdermal fentanyl had a lower annual incidence density and risk of constipation than oxycodone CR and morphine CR (P > 0.05). After adjusting for confounding variables, including race and supplemental opioid use, the adjusted risk of constipation was 78% greater in the oxycodone CR group (P = 0.0337) and 44% greater in the morphine CR group (P = 0.2242) than in the transdermal fentanyl group.


Conclusion: In this population, patients receiving transdermal fentanyl had a lower risk of developing constipation compared with those receiving oxycodone CR or morphine CR.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Gutstein HB, Akil H. Opioid analgesics, in Hardman JG, Limbird LE, Gilman AG (eds): Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York, McGraw-Hill Professional, 2001, ed 10, pp 569–619.
 
2. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001; 322: 1154–1158.
 
3. Donner B, Zenz M, Tryba M, et al. Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain. Pain 1996; 64: 527–534.
 
4. Donner B, Zenz M. Transdermal fentanyl: A new step on the therapeutic ladder. Anticancer Drugs 1995; 6 (Suppl 3): 39–43.
 
5. Radbruch L, Sabatowski R, Loick G, et al. Constipation and the use of laxatives: A comparison between transdermal fentanyl and oral morphine. Palliat Med 2000; 14: 111–119.
 
6. Donner B, Zenz M, Strumpf M, et al. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 1998; 15: 168–175.
 
7. Ahmedzai S, Brooks D; The TTS-Fentanyl Comparative Trial Group. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. J Pain Symptom Manage 1997; 13: 254–261.
 
8. De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther 1996; 69: 103–115.
 
9. Megens AA, Artois K, Vermeire J, et al. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage 1998; 15: 253–257.
 
10. Pasternak GW. Insights into μ opioid pharmacology: The role of μ opioid receptor subtypes. Life Sci 2001; 68: 2213–2219.
 
11. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: A double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999; 26: 862–869.
 
12. Maier C, Hildebrandt J, Klinger R, et al. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain: Results of a double-blind placebo-controlled trial (MONTAS). Pain 2002; 97: 223–233.
 
13. Cameron JC. Constipation related to narcotic therapy: A protocol for nurses and patients. Cancer Nurs 1992; 15: 372–377.
 
14. Robinson CB, Fritch M, Hullett L, et al. Development of a protocol to prevent opioid-induced constipation in patients with cancer: A research utilization project. Clin J Oncol Nurs 2000; 4: 79–84.